Coya Therapeutics, Inc. (COYA)
NASDAQ: COYA · Real-Time Price · USD
5.47
-0.08 (-1.53%)
Dec 26, 2025, 9:53 AM EST - Market open
Coya Therapeutics Revenue
Coya Therapeutics had revenue of $3.56M in the quarter ending September 30, 2025. This brings the company's revenue in the last twelve months to $3.99M, down -58.26% year-over-year. In the year 2024, Coya Therapeutics had annual revenue of $3.55M, down -40.79%.
Revenue (ttm)
$3.99M
Revenue Growth
-58.26%
P/S Ratio
23.15
Revenue / Employee
$498,463
Employees
8
Market Cap
114.35M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.55M | -2.45M | -40.79% |
| Dec 31, 2023 | 6.00M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
COYA News
- 3 days ago - Coya Therapeutics Receives Clinical Trial Application (CTA) Acceptance from Health Canada to Proceed with the COYA 302 ALSTARS Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS) - Business Wire
- 17 days ago - Coya Therapeutics Announces Patients Have Been Dosed in the ALSTARS Trial of COYA 302 for the Treatment of ALS - Business Wire
- 4 weeks ago - Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences - Business Wire
- 6 weeks ago - Coya Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update - Business Wire
- 7 weeks ago - Coya Therapeutics Announces That Its Combination LD IL-2/GLP-1 RA Candidate (COYA 303) Demonstrated Potent Systemic and Brain Anti-Inflammatory Efficacy In Vivo - Business Wire
- 2 months ago - Coya Therapeutics Announces Closing of $23.0 Million Upsized Public Offering of Common Stock, Including Full Exercise of Underwriter's Option to Purchase Additional Shares - Business Wire
- 2 months ago - Coya Therapeutics Announces Pricing of $20 Million Upsized Public Offering of Common Stock - Business Wire
- 2 months ago - Coya Therapeutics Announces Proposed Public Offering of Common Stock - Business Wire